Andreas Norlin

Andreas Norlin, PhD, is an experienced R&D leader at Ascelia Pharma, a biotech dedicated to orphan oncology treatments. With over 25 years in academia, biotech, and big pharma, he specializes in guiding preclinical and clinical drug development strategies. Andreas oversees programs such as Orviglance®, an oral MRI contrast agent for detecting liver metastases in cancer patients and the oral chemotherapy candidate Oncoral®. His leadership spans project and portfolio management, regulatory strategy, pharmacology, toxicology, and cross-functional partnerships. A patient-centric and collaborative leader, he ensures robust data-driven progression to bring novel oncology therapies to market.